Sign in

Nature Reviews Drug Discovery

@natrevdrugdiscov.nature.com
5.2K followers 55 following 442 posts

Editorial team of Nature Reviews Drug Discovery www.nature.com/nrd

PostsRepliesMedia
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 15h
For readers interested in the pipeline of drugs to treat chronic obstructive pulmonary disease (COPD), here's a comprehensive review www.nature.com/articles/s41... rdcu.be/BhP4KUSSns2a
nature.com
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities   - Nature Reviews Drug Discovery
Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a complex network of inflammatory proce...
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 15h
COPD trial wins spur broad respiratory hopes nature.com/articles/d41... AstraZeneca’s tozorakimab reduced disease flare ups in patients with COPD, suggesting IL-33-targeted antibodies could offer broad potential in lung diseases. Read about the COPD pipeline in this news feature
Table of drugs in development for COPD
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 02/10/2026
The cellular landscape of druggable RNA-binding proteins nature.com/articles/s41... rdcu.be/Xdw8gA2w82Ea This new Perspective discusses opportunities to therapeutically target RNA-binding proteins, which are involved in the development of multiple diseases
nature.com
The cellular landscape of druggable RNA-binding proteins - Nature Reviews Drug Discovery
RNA-binding proteins (RBPs) regulate every step of cellular RNA metabolism, and their dysregulation contributes to many diseases. This Perspective describes the endogenous and disease-linked roles of ...
010
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 29/09/2026
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity nature.com/articles/s41... rdcu.be/4VH5Q2Uzx71a This new Review discusses how understanding of signalling mechanisms of the cytokine IL-6 could guide the discovery of safer and more effective drugs
nature.com
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity - Nature Reviews Drug Discovery
IL-6-targeted therapies have transformed the treatment of autoimmune diseases, but safety concerns related to the cytokine’s homeostatic functions remain. This Review examines classic and trans-signal...
011
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 29/09/2026
Our October issue is live! Read about mRNA therapeutics, orexin receptor agonists for narcolepsy, targeting T follicular helper cells, simulation-guided clinical trials and more here nature.com/nrd/volumes/...
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 21/09/2026
The evolving landscape of drug targets www.nature.com/articles/s41... rdcu.be/22o1FPpNJ3Ga In the past 25 years, advances in areas such as genomics and the diversification of therapeutic modalities have expanded the drug target landscape. It now includes ~700 targets, as mapped in this new Review
Figure showing the drug target landscape by target type and modality
130
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 18/09/2026
Drugs that target myostatin signalling are among the most advanced in development to strengthen muscle for healthy ageing. Read about this and the other approaches being explored in this Review nature.com/articles/s41... rdcu.be/EVPsY9k2CTGa
nature.com
Strengthening muscle for healthy ageing: innovative treatments for sarcopenia - Nature Reviews Drug Discovery
There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and meta...
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 18/09/2026
First myostatin-targeted antibody approved for spinal muscular atrophy nature.com/articles/d41... Scholar Rock’s apitegromab has received FDA approval for SMA. Drug developers hope the drug class could be applied in other settings such as muscle preservation during weight loss
Screenshot of article
011
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 17/09/2026
A translational framework for extrahepatic oligonucleotide delivery nature.com/articles/d41... This Comment article outlines an industry-grade quality framework to eliminate methodological artifacts and ensure the translational and commercial viability of novel oligonucleotide platforms
001
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 16/09/2026
Upcoming FDA approval decisions in Q4 2026 www.nature.com/articles/d41... Notable potential approvals include a first-in-class B7H3-targeted ADC for small-cell lung cancer, an ASO for chronic hepatitis B infection and a PD1 x VEGF bispecific antibody for non-small-cell lung cancer
nature.com
Upcoming FDA approval decisions in Q4 2026
Discover the world’s best science and medicine | Nature.com
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 15/09/2026
This Review in the September issue covers the clinical landscape for agonistic antibody-based immunotherapy for cancer and immune disorders, and mechanistic insights that could broaden its scope www.nature.com/articles/s41... rdcu.be/9y7jJZbHxe8a
nature.com
Realizing the potential of agonistic antibody immunotherapy - Nature Reviews Drug Discovery
Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and...
010
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 14/09/2026
This Review in the September issue discusses targeting autophagy to limit malignant transformation, potentiate cancer cell death driven by existing drugs and restore immunosurveillance in support of immunotherapies www.nature.com/articles/s41... rdcu.be/MMNGMaj8ifwa
nature.com
Autophagy modulation in cancer - Nature Reviews Drug Discovery
Autophagy has a highly complex and context-dependent role in cancer, challenging the development of autophagy-modulating strategies. This Review discusses the potential of targeting autophagy to count...
032
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 11/09/2026
Newest glue degrader nabs multiple myeloma approval www.nature.com/articles/d41... Iberdomide (Zenbexus; Bristol Myers Squibb) is an “important proof point” for targeted protein degradation, showing how new molecular glue degraders can improve on their predecessors
nature.com
Newest glue degrader nabs multiple myeloma approval
Discover the world’s best science and medicine | Nature.com
011
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 10/09/2026
For readers interested in the potential of in vivo CAR-T cell therapies for cancer and autoimmune diseases, here's a comprehensive review by pioneers in the field rdcu.be/koc33UDidsza nature.com/articles/s41...
020
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 10/09/2026
The landscape for in vivo CAR T cell therapies www.nature.com/articles/d41... This article analyses the pipeline of in vivo CAR-T therapies for cancer and autoimmune disorders, highlighting trends in delivery technologies, targets and indications.
nature.com
The landscape for in vivo CAR T cell therapies
Discover the world’s best science and medicine | Nature.com
020
Reposted by Nature Reviews Drug Discovery
CeMM @cemm.oeaw.ac.at · 10/09/2026
🧠 Solute carrier membrane transporters are drug targets in the central nervous system & their therapeutic potential may extend much further. In Nature Reviews Drug Discovery, @supertifurgalab.bsky.social & Solgate explore new opportunities for #SLCs in CNS drug discovery. 🔗 bit.ly/4xiIFFd
131
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 09/09/2026
This Review in the September issue discusses the evolving landscape of drugs targeting claudins in cancer, including monoclonal antibodies, CAR-T cell therapies, antibody-drug conjugates and bispecific antibodies www.nature.com/articles/s41... rdcu.be/vcwJ2mgqPs3a
nature.com
Targeting claudins in cancer - Nature Reviews Drug Discovery
Claudins are emerging as clinically actionable targets in cancer, exemplified by the approval of CLDN-18.2-directed therapy. This review examines the biological basis and therapeutic exploitation of c...
041
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 08/09/2026
Strengthening muscle for healthy ageing: innovative treatments for sarcopenia www.nature.com/articles/s41... rdcu.be/NVL9v7ueUwAa This new Review discusses strategies targeting mitochondrial function, autophagy, anabolic signalling, vascularization, inflammageing and regeneration
nature.com
Strengthening muscle for healthy ageing: innovative treatments for sarcopenia - Nature Reviews Drug Discovery
There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and meta...
010
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 07/09/2026
Un-siloed biomedical opportunities www.nature.com/articles/d41... Edith Heard, CEO of the Francis Crick Institute in London @crick.ac.uk, discusses the need to break down biomedical boundaries
Screenshot of interview
020
Reposted by Nature Reviews Drug Discovery
David Shaywitz @dshaywitz.bsky.social · 08/08/2026
1/4 Delighted (+relieved) our @natrevdrugdiscov.nature.com perspective on AI in R&D finally out. Channeling R. Solow: why do we see AI everywhere in biopharma except in the productivity statistics? As we write, evidence of its clinically relevant impact remains “disappointingly limited.”
172
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 04/09/2026
The FDA recently approved the first orexin receptor agonist for narcolepsy nature.com/articles/d41... Oveporexton is anticipated to transform the treatment of this sleep disorder, and potential additional applications have led to the class being dubbed the GLP-1s of neuroscience
Table of orexin receptor 2 agonists in development
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/09/2026
For readers interested in the opportunities and pitfalls for CAR-T therapies for autoimmune diseases, here's a recent comprehensive Review www.nature.com/articles/s41... rdcu.be/97VgTv2SaRTa
nature.com
Roads and detours for CAR T cell therapy in autoimmune diseases - Nature Reviews Drug Discovery
Following on from its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy has been extended to treat autoimmune diseases. This Review discusses the precl...
063
Reposted by Nature Reviews Drug Discovery
Lupus Foundation of America @lupus.org · 01/09/2026
Novartis and Bristol Myers Squibb have paused their CAR-T trials for #lupus and other autoimmune diseases to review safety concerns. CAR-T remains experimental, and continued research is needed to understand its benefits and risks. Read the announcement: buff.ly/QJBbN7L
132
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 02/09/2026
Solute carrier membrane transporters: emerging targets in CNS disorders www.nature.com/articles/s41... rdcu.be/uQeAYKzFg8Ua This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy
Strategies to target SLC transporters
030
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 01/09/2026
For readers interested in JAK inhibitors for autoimmmune diseases, such as Roivant's brepocitinib that has just been approved by the FDA for dermatomyositis, here's a review on pharmacological targeting of the JAK-STAT pathway nature.com/articles/s41... rdcu.be/rpNrcuDMf4ha
Targeting JAK-STAT signalling
042
Reposted by Nature Reviews Drug Discovery
Scott Bagley @bagphos.bsky.social · 28/08/2026
The FDA has approved brepocitinib as a TYK2/JAK1 inhibitor from Roivant/Priovant Huge shout out to the #PfizerChemistry team who discovered the molecule - it was a large project team and when I joined the mol had already been identified and… #ChemSky 1/…
Chemical structure of brepocitinib.
4264
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 01/09/2026
Our September issue is live! Read about brain-shuttle biologics, targeting claudins in cancer, agonist antibody-based immunotherapies, autophagy modulation in cancer and more here nature.com/nrd/volumes/...
Screenshot of table of contents
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 26/08/2026
Towards precision psychiatry: initial foundations and future directions www.nature.com/articles/s41... rdcu.be/fCeOU This new Perspective discusses how to align drug development with underlying neural dysfunctions using patient-specific measures of brain function such as EEG
nature.com
Towards precision psychiatry: initial foundations and future directions - Nature Reviews Drug Discovery
Drug discovery for psychiatric disorders is a slow and challenging process, driven in part by reliance on symptom-based diagnostic criteria that fail to capture the underlying disease biology. In thei...
021
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 26/08/2026
For neurologists who want to stay current, Springer Nature has a new resource made for you. Nature Briefing: Clinical Neurology brings together key clinical developments and research from leading journals in the field in a weekly newsletter. Sign up is free go.springernature.com/int1/briefin...
go.springernature.com
Sign up for Nature Briefing: Clinical Neurology
031
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 21/08/2026
For readers interested in mRNA therapeutics, including neoantigen-based therapeutic cancer vaccines such as Moderna and Merck's intismeran autogene, here's a recent Review www.nature.com/articles/s41... rdcu.be/fBiGZ
Process by which therapeutic mRNA cancer vaccines are produced
020
Reposted by Nature Reviews Drug Discovery
The New York Times @nytimes.com · 19/08/2026
An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched trial, the pharmaceutical companies Moderna and Merck announced Wednesday.
nyti.ms
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
16337124
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 14/08/2026
In the wake of the FDA approval of Takeda's first-in-class orexin 2 receptor agonist oveporexton for narcolepsy last week, there is a burgeoning pipeline of orexin modulators for a range of central nervous system disorders nature.com/articles/d41...
nature.com
Orexin receptor agonist secures landmark narcolepsy approval
As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 12/08/2026
Oncolytic virus nabs FDA approval nature.com/articles/d41... Replimune’s vusolimogene oderparepvec (Tudriqev, also known as RP1) has received accelerated approval for use in combination with the PD-1 blocker nivolumab for advanced melanoma. It is the second oncolytic virus to reach the US market
000
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 11/08/2026
For readers interested in targeted protein degradation, this Perspective in the August issue discusses safety considerations in the development of PROTAC and molecule glue drug candidates that recruit the E3 ligase cereblon www.nature.com/articles/s41... rdcu.be/fzgJJ
041
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 10/08/2026
Orexin receptor agonist secures landmark narcolepsy approval nature.com/articles/d41... As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists
021
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 10/08/2026
Artificial intelligence in drug discovery — what it is, where we stand and the path forward nature.com/articles/s41... rdcu.be/fyUFz
032
Reposted by Nature Reviews Drug Discovery
Derek Lowe @dereklowe.bsky.social · 05/08/2026
science.org
We Only Know Her as Mei
44722
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 05/08/2026
For readers interested in 'in vivo' CAR-T therapies for cancer and autoimmune diseases, here's a comprehensive review from pioneers in the field nature.com/articles/s41... rdcu.be/fx2H3
nature.com
In vivo chimeric antigen receptor (CAR)-T cell therapy - Nature Reviews Drug Discovery
In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging v...
011
Reposted by Nature Reviews Drug Discovery
Bloomberg News @bloomberg.com · 30/07/2026
Johnson & Johnson announced collaboration with privately held Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases, J&J said in a statement
bloom.bg
J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion
Johnson & Johnson announced a collaboration with Sail Biomedicines to develop CAR-T therapies for immune diseases and said it now has an exclusive option to acquire the closely held company.
0134
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 04/08/2026
For readers interested in mRNA therapeutics, this Review discusses progress and lessons learned from candidates in clinical trials for applications including cancer immunotherapy, genome editing and in vivo CAR-T cell therapy www.nature.com/articles/s41... rdcu.be/fxNFo
nature.com
Towards mRNA therapeutics 2.0 - Nature Reviews Drug Discovery
mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzym...
040
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 04/08/2026
Our latest research highlight covers a paper in Nature on a novel RNA modification that could improve the characteristics of mRNA-based therapeutics www.nature.com/articles/d41...
nature.com
Optimizing translation of therapeutic mRNAs
Discover the world’s best science and medicine | Nature.com
032
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/08/2026
Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors - find out more in this news story in our August issue www.nature.com/articles/d41...
Table of multispecific T-cell engagers in development
010
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/08/2026
Our August issue is live! Read about multispecific T-cell engagers for cancer, the design of small-molecule kinase inhibitors, the evolution of pharmacotherapy for obesity, safety considerations for targeted protein degraders and more here www.nature.com/nrd/volumes/...
August issue contents
000
Reposted by Nature Reviews Drug Discovery
Waggoner Lab @labwaggoner.bsky.social · 24/07/2026
Review @natrevdrugdiscov.nature.com Targeting T follicular helper cells for lifelong health www.nature.com/articles/s41...
052
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 31/07/2026
Oral macrocyclic PCSK9 inhibitor secures FDA approval nature.com/articles/d41... Merck & Co.’s enlicitide has been approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia
nature.com
Oral macrocyclic PCSK9 inhibitor secures FDA approval
Discover the world’s best science and medicine | Nature.com
001
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 30/07/2026
For readers interested in drug discovery targeting GPCRs, this Review covers trends in the field: www.nature.com/articles/s41... rdcu.be/fwSqG and this Review covers opportunities from understanding of functional dynamics: www.nature.com/articles/s41... rdcu.be/fwSrj
040
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 30/07/2026
Our latest Research Highlight covers a paper in Nature on the discovery of small-molecule inhibitors of β-arrestins, which are important transducers of signalling via G protein-coupled receptors (GPCRs) www.nature.com/articles/d41...
nature.com
Small molecules stop β-arrestins
Discover the world’s best science and medicine | Nature.com
010
Reposted by Nature Reviews Drug Discovery
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 27/07/2026
Targeting T follicular helper cells for lifelong health nature.com/articles/s41... rdcu.be/fwdMi This new Review discusses therapeutic strategies to modulate T follicular helper (TFH) cells, which support B cell function to promote long-lasting antibody responses
nature.com
Targeting T follicular helper cells for lifelong health - Nature Reviews Drug Discovery
T follicular helper (TFH) cells support B cell function to promote long-lasting antibody responses but are implicated in many diseases and undergo age-related changes. This Review explores emerging th...
021
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 27/07/2026
Targeting T follicular helper cells for lifelong health nature.com/articles/s41... rdcu.be/fwdMi This new Review discusses therapeutic strategies to modulate T follicular helper (TFH) cells, which support B cell function to promote long-lasting antibody responses
nature.com
Targeting T follicular helper cells for lifelong health - Nature Reviews Drug Discovery
T follicular helper (TFH) cells support B cell function to promote long-lasting antibody responses but are implicated in many diseases and undergo age-related changes. This Review explores emerging th...
021
Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 22/07/2026
Multispecific molecules are transforming pharmacotherapy - find out more about the different types in this Perspective by Raymond Deshaies, one of the pioneers in the field www.nature.com/articles/s41... rdcu.be/fvaFS
nature.com
How multispecific molecules are transforming pharmacotherapy - Nature Reviews Drug Discovery
Multispecific drugs are designed to engage two or more entities to exert their pharmacological effect. This Perspective discusses how a new wave of FDA-approved multispecific molecules have been trans...
020